@Article{oncologie.2020.014125,
AUTHOR = {Nan Geng, Wenxia Hu, Zhikun Liu, Jingwei Su, Wenyu Sun, Shaonan Xie, Cuimin Ding},
TITLE = {LncRNA-ATB Can Be a Biomarker for Diagnosis and Prognosis Evaluation of  Non-Small Cell Lung Cancer},
JOURNAL = {Oncologie},
VOLUME = {22},
YEAR = {2020},
NUMBER = {4},
PAGES = {245--254},
URL = {http://www.techscience.com/oncologie/v22n4/40860},
ISSN = {1765-2839},
ABSTRACT = {Objective: This study was set out to inquire into the expression and 
clinical significance of lncRNA activated by transforming growth factor β 
(LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer 
(NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89 
NSCLC patients was detected by quantitative real-time polymerase chain reaction 
(qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver 
operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression 
groups. The 3-year survival rate was calculated using Kaplan-Meier method and logrank test, and compared between lncRNA-ATB high and low expression groups by 
Log-rank test. Cox regression quantitatively analyzed the correlation between 
lncRNA-ATB and the clinical prognosis of NSCLC patients. Results: LncRNAATB presented notably higher expression in NSCLC tissues as compared to adjacent 
tissues (P < 0.05), and was linked to smoking history, TNM stage and greatest tumor 
diameter (GTD) (P < 0.05). The cut-off value, sensitivity and specificity, as well as 
the area under the curve (AUC) of NSCLC diagnosed by LncRNA-ATB were 2.103, 
73.77%, 83.15% and 0.836, respectively. Patients with high lncRNA-ATB
expression (40.00%) showed statistically lower than those with low lncRNA-ATB
expression (63.36%). TNM stage, differentiation degree and lncRNA-ATB
expression were independent variables affecting patient prognosis. Conclusions: 
LncRNA-ATB, with increased expression profiles in NSCLC tissues, is involved in 
NSCLC progression and associated with unfavourable prognosis of patients, which 
can be a plausible tumor marker for NSCLC patients.},
DOI = {10.32604/oncologie.2020.014125}
}